Return to CG81 Overview

Advanced breast cancer: diagnosis and treatment [CG81]

Measuring the use of this guidance

Recommendation: 1.1.6

On recurrence, consider reassessing oestrogen receptor (ER) and human epidermal growth factor 2 receptor (HER2) status if a change in receptor status will lead to a change in management.

What was measured: Proportion of NHS trusts in England that routinely perform HER2 testing for people with advanced breast cancer.
Data collection end: March 2017
93%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.

What was measured: Proportion of women aged 50-69 years, with newly diagnosed metastatic breast cancer whose ER status was known.
Data collection end: July 2018
77%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.

What was measured: Proportion of women aged 70+ years, with newly diagnosed metastatic breast cancer whose ER status was known.
Data collection end: July 2018
72%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.


Recommendation: 1.3.1

Offer endocrine therapy as first-line treatment for the majority of patients with ER-positive advanced breast cancer. [2009]

What was measured: Proportion of women aged 50-69 years with ER-positive metastatic breast cancer, who received endocrine treatment.
Data collection end: July 2018
57%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.

What was measured: Proportion of women aged 70+ years with ER-positive metastatic breast cancer, who received endocrine treatment.
Data collection end: July 2018
76%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.


Recommendation: 1.3.2

Offer chemotherapy as first-line treatment for patients with ER positive advanced breast cancer whose disease is imminently life-threatening or requires early relief of symptoms because of significant visceral organ involvement, providing they understand and are prepared to accept the toxicity. [2009]

What was measured: Proportion of women aged 50-69 years, with newly diagnosed metastatic breast cancer who received chemotherapy.
Data collection end: July 2018
59%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.

What was measured: Proportion of women aged 70+ years, with newly diagnosed metastatic breast cancer who received chemotherapy.
Data collection end: July 2018
24%
Area covered: England and Wales
Source: Royal College of Surgeons. National Audit of Breast Cancer in Older Patients.



 Return to CG81 Overview